Benzinga | Dec 20, 2021 06:16AM EST

BeiGene Expands Collaboration With Novartis To Develop And Commercialize BeiGene's TIGIT Inhibitor And Market Five Novartis Oncology Medicines In China Broad Markets

Strategic collaboration expected to advance clinical development of ociperlimab in combination with tislelizumab, including initiation and funding by Novartis of additional studies

BeiGene expands commercial portfolio in China broad markets with marketing rights for five Novartis Oncology products